First patient dosed with PyL, a PSMA-targeted PET/CT imaging agent for prostate cancer

Progenics Pharmaceuticals announced that its first patient has been dosed in the company’s phase 2/3 clinical trial of PSMA-Target PET/CT imaging agent, PyL, which it will be evaluating for diagnostic accuracy. Progenics Pharmaceuticals, which develops medicine and other products targeting the treatment of cancer, dosed their first patient at Yale School of Medicine and plans to enroll about 300 patients with high risk prostate cancer with recurrence or metastatic disease in the U.S. and Canada for this part of the study. Read more.